Wednesday, May 20, 2026 at 12-1pm ET                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is a chronic, progressive condition affecting 1:200 to 1:500 individuals in the US.^1,2
• Despite available standard-of-care therapies, patients may experience impaired functional capacity and disease progression, driving the need for therapies that target the underlying oHCM pathophysiology rather than symptoms alone.^2-4
• This webinar will be led by Rachel Lavelle, PharmD, who brings complementary clinical and managed care perspectives on oHCM, combining deep experience in cardiology care, guideline-directed therapy implementation, and value-focused cardiovascular outcomes.

Learning Objectives

• Understand oHCM pathophysiology, diagnosis, and management
• Introduction of a new treatment for patients with oHCM

Speaker:

Rachel Lavelle, PharmD, BCCP
Clinical Pharmacy Specialist, Cardiology
University of Chicago Medicine

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.

References: 1. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249-1254. 2. Butzner M, Rowin E, Yakubu A, et al. Clinical characteristics and healthcare resource utilization among patients with obstructive hypertrophic cardiomyopathy treated in a range of settings in the United States. J Clin Med. 2022;11(13):3898. 3. Naidu SS, Sutton MB, Gao W, et al. Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States. J Med Econ. 2023;26(1):682-690. 4. Ommen SR, Ho CY, Asif IM, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2024;149(23):e1239-e1311.

US-MYQ-00265 04/2026